KTTA Pasithea Therapeutics
- 5.4600
- -0.3900-6.67%
Pasithea Therapeutics News
ARS: Annual Report to Security Holders
DEF 14A: Definitive information statements
8-K: Current report
10-Q: Quarterly report
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Marques Tiago
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director Dumesnil Simon
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Schneiderman Daniel H
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director Leahy Emer
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director Novak Alfred J
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Currie Graeme Martin
Pasithea Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director STEINMAN LAWRENCE
Pasithea Therapeutics | EFFECT: Others
Pasithea Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Pasithea Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Pasithea Therapeutics | 10-K: Annual report
Pasithea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director STEINMAN LAWRENCE
Pasithea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schneiderman Daniel H
Pasithea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Novak Alfred J
Pasithea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Marques Tiago
Pasithea Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Leahy Emer
Analysis
Price Target
No Data
